You are here

Global Neuromodulation Devices Market Forecast Report 2019-2026

DUBLIN, Oct. 1, 2019 /PRNewswire/ -- The "Neuromodulation Devices Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The neuromodulation devices global market is expected to reach $9,917.0 million by 2026 growing at a high single-digit CAGR from 2019 to 2026 due to increasing incidence of chronic pain, increasing Parkinson's and Alzheimer's disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. The neuromodulation devices market is segmented by product, application, end-user, and geography.

North America accounted for the largest revenue in 2019 and is expected to grow at a high single-digit CAGR from 2019 to 2026 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices.

The Asia-Pacific is the fastest-growing region with a double-digit CAGR from 2019 to 2026 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares.

Some of the major players in Neuromodulation devices market include

  • Medtronic Plc (Ireland)
  • Abbott Laboratories (U.S.)
  • Boston Scientific Corporation (U.S.)
  • LivaNova Plc (U.K.)
  • Nevro Corporation (U.S.)
  • Inspire Medical System,
  • Inc. (U.S.)
  • Nuvectra (U.S.)
  • Neuropace Inc. (U.S.)
  • Bioness Inc. (U.S.)
  • Beijing PINS Medical Co., Ltd. (China)
  • Laborie Medical (Canada)
  • Neuronetics, Inc. (U.S.).

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Takeaways
2.2 Scope Of The Report
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increasing Incidence Of Chronic Pain
3.3.1.2 Increasing Parkinson's And Alzheimer's Disorder's
3.3.1.3 Low Approval Rate Of CNS Drugs Is Driving Neuromodulation Market
3.3.1.4 Favorable Reimbursement Scenario In Major Markets
3.3.1.5 The Emergence Of Neuromodulation As Add On Therapy
3.3.1.6 Technological Innovations In Neuromodulation
3.3.1.7 Expansion In Emerging Markets
3.3.1.8 The Rise In The Number Of Clinical Studies Performed
3.3.2 Restraints And Threats
3.3.2.1 Side Effects And Risks Associated With The Use
3.3.2.2 Lack Of Trained Professionals
3.3.2.3 Availability Of Alternative Treatments
3.3.2.4 Stringent Regulatory Guidelines
3.4 Regulatory Affairs
3.4.1 International Organization For Standardization
3.4.1.1 ISO 9001: 2015 Quality Management System
3.4.1.2 ISO 13485 Medical Devices
3.4.1.3 ISO 10993 Biological Evaluation Of Medical Devices
3.5 Clinical Trials Data
3.6 Technological Advancements
3.6.1 Rechargeable Systems
3.6.2 Optogenetic Technology
3.6.3 Focused Ultrasound (Fus)
3.6.4 Miniaturization
3.6.5 Portable Neuromodulation Systems (Pons)
3.6.6 Wearable Pain Management Technology
3.6.7 Trans-Spinal Direct Current Stimulation (Tsdcs)
3.6.8 Nano-Neuromodulation
3.6.9 Bioactive Coatings
3.7 Porter's Five Force Analysis
3.7.1 Threat Of New Entrants
3.7.2 Threat Of Substitutes
3.7.3 Bargaining Power Of Suppliers
3.7.4 Bargaining Power Of Buyers
3.7.5 Competitive Rivalry
3.8 Supply Chain Analysis
3.9 Reimbursement Scenario
3.9.1 Reimbursement Table
3.10 Regulatory Approved Neuromodulation Devices
3.10.1 Spinal Cord Stimulators (Scs)
3.10.2 Transcutaneous Electrical Nerve Stimulator (Tens)
3.10.3 Deep Brain Stimulation (Dbs)
3.10.4 Sacral Nerve Stimulation (Sns)
3.10.5 Vagus Nerve Stimulation (Vns)
3.10.6 Transcranial Magnetic Stimulation (Tms)
3.11 Funding Scenario
3.12 Market Share Analysis By Major Players
3.12.1 Neuromodulation Devices Global Market Share Analysis
3.12.2 Spinal Cord Stimulators Global Market Share Analysis
3.12.3 Deep Brain Stimulators Global Market Share Analysis
3.13 Neuromodulation Devices Number Of Units By Region
3.13.1 Spinal Cord Stimulation (Scs) Number Of Units By Region
3.13.2 Deep Brain Stimulation (Dbs) Number Of Units By Region
3.13.3 Sacral Nerve Stimulation (Sns) Number Of Units By Region
3.13.4 Vagus Nerve Stimulation (Vns) Number Of Units By Region
3.13.5 Transcutaneous Electrical Nerve Stimulation (Tens) Number Of Units By Region
3.13.6 Neuromuscular Electrical Stimulation (Nmes) Number Of Units By Region
3.14 Market Penetration
3.15 Neuromodulation Devices Company Comparison Table By Revenue, Technology, Products And Application

4 Neuromodulation Devices Global Market, By Product
4.1 Introduction
4.2 Internal Neuromodulation Devices
4.2.1 Spinal Cord Stimulation (Scs)
4.2.2 Deep Brain Stimulation (Dbs)
4.2.3 Sacral Nerve Stimulation (Sns)
4.2.4 Vagus Nerve Stimulation (Vns)
4.2.5 Other Internal Neuromodulation Devices
4.3 External Neuromodulation Devices
4.3.1 Transcutaneous Electrical Nerve Stimulation (Tens)
4.3.2 Neuromuscular Electrical Stimulation (Nmes)
4.3.3 Other External Neuromodulation Devices

5 Neuromodulation Devices Global Market, By Application
5.1 Introduction
5.2 Pain Management
5.2.1 Chronic Pain
5.2.2 Failed Back Surgery Syndrome (Fbss)
5.2.3 Other Pain Management
5.3 Central Nervous System (Cns)
5.3.1 Parkinson's Disease
5.3.2 Essential Tremors
5.3.3 Dystonia
5.3.4 Epilepsy
5.3.5 Depression
5.3.6 Other Cns
5.4 Gastroenterology And Urology
5.4.1 Gastroparesis
5.4.2 Urinary Incontinence
5.4.3 Faecal Incontinence
5.5 Other Applications

6 Neuromodulation Devices Global Market, By End-Users
6.1 Introduction
6.2 Hospitals And Ambulatory Surgery Centers (Asc)
6.3 Clinics And Physiotherapy Centers
6.4 Academics And Research

7 Regional Analysis

8 Competitive Landscape
8.1 Introduction
8.2 Product Approval
8.3 New Product Launch
8.4 Agreements And Partnerships
8.5 Others

9 Major Companies

Companies Mentioned

  • Abbott Laboratories
  • Ates Medica Device srl
  • Atrotech Oy
  • Avery Biomedical Devices Inc.
  • Axilum Robotics
  • Axonics Modulation Technologies, Inc.
  • Axon Therapies, Inc.
  • Beijing Pins Medical Co., Ltd.
  • Bioness Inc.
  • Biocontrol Medical Ltd.
  • Bioinduction Ltd.
  • Bluewind Medical
  • Boston Scientific Corp.
  • Brainbox Ltd.
  • Brainsway
  • Cala Health
  • Cortec GmbH
  • Cvrx, Inc.
  • Cymedica Orthopedics
  • Desyncra
  • Djo Global (Colfax)
  • Dw Healthcare (Cefaly Technology)
  • Dynamd
  • EB Neuro S.P.A.
  • Electrocore, Inc.
  • Eneura Inc.
  • Gimer Medical
  • GTX Medical
  • Helius Medical Technologies
  • Heuro Canada
  • Innoncon Medical
  • Inspire Medical Systems, Inc.
  • Laborie Medical System Inc.
  • Livanova plc
  • Magstim Tms
  • Magventure A/S
  • Mainstay Medical
  • Medtronic plc
  • Metacure, Ltd.
  • Micro Transponder Inc.
  • Nevro Corporation
  • Neurocare Group GmbH
  • Neuroelectrics
  • Neurolief Ltd.
  • Neuronano AB
  • Neuronetics
  • Neuropace Inc.
  • Neurometrix, Inc.
  • Neuromod Devices Ltd.
  • Neuros Medical, Inc.
  • Neuroem Therapeutics
  • IST, LLC (Neurofus)
  • Neurosigma Inc.
  • Neurovalens Ltd. (Modius Health)
  • Nexstim, plc
  • Nuraleve Inc.
  • Nuvectra
  • Nyxoah SA
  • Od Stock Medical
  • Orchestra Biomed
  • Pathmaker Neurosystems Inc.
  • Precisis AG
  • Remed Co., Ltd
  • Reshape Lifesciences, Inc.
  • Respicardia, Inc.
  • Saluda Medical
  • Sceneray Corporation Ltd.
  • Set Point Medical
  • Sooma Oy
  • Spr Therapeutics
  • Stimwave LLC
  • Synapse Biomedical Inc.
  • Syneika
  • Theranica Bio-Electronics Ltd.
  • Tivic Health
  • Tvns Technologies GmbH
  • Ybrain, Inc.
  • Zynex Medical, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/4anray

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-neuromodulation-devices-market-forecast-report-2019-2026-300928755.html

SOURCE Research and Markets